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ABSTRACT
Immunoglobulin G (IgG) based tests for the diagnosis of active tuberculosis (TB) 
disease often show a lack of specificity in TB endemic regions, which is mainly due to a 
high background prevalence of LTBI. Here, we investigated the combined performance 
of the responses of different Ig classes to selected mycobacterial antigens in primary 
healthcare clinic attendees with signs and symptoms suggestive of TB. The sensitivity 
and specificity of IgA, IgG and/or IgM to LAM and 7 mycobacterial protein antigens 
(ESAT-6, Tpx, PstS1, AlaDH, MPT64, 16kDa and 19kDa) and 2 antigen combinations 
(TUB, TB-LTBI) in the plasma of 63 individuals who underwent diagnostic work-up 
for TB after presenting with symptoms and signs compatible with possible active 
TB were evaluated. Active TB was excluded in 42 individuals of whom 21 has LTBI 
whereas active TB was confirmed in 21 patients of whom 19 had a follow-up blood 
draw at the end of 6-month anti-TB treatment. The leading single serodiagnostic 
markers to differentiate between the presence or absence of active TB were anti-16 
kDa IgA, anti-MPT64 IgA with sensitivity and specificity of 90%/90% and 95%/90%, 
respectively. The combined use of 3 or 4 antibodies further improved this performance 
to accuracies above 95%. After successful completion of anti-TB treatment at month 
6, the levels of 16 kDa IgA and 16 kDa IgM dropped significantly whereas LAM IgG and 
TB-LTBI IgG increased. These results show the potential of extending investigation 
of anti-tuberculous IgG responses to include IgM and IgA responses against selected 
protein and non-protein antigens in differentiating active TB from other respiratory 
diseases in TB endemic settings.
INTRODUCTION
Tuberculosis (TB) still remains a global threat to 
mankind and although the millennium development goals 
target of halting and reversing the increasing incidence 
of TB globally was achieved, TB still killed 1.5 million 
people in 2014 [1]. The currently available diagnostic tools 
have many limitations including poor sensitivity (smear 
microscopy), long turn-around time (culture), the use of 
expensive tools and the difficulty to develop these tests 
into point-of-care (POC) tests [2]. The high prevalence 
of latent tuberculosis infection (LTBI), in addition to high 
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TB and HIV co-infection in resource-poor settings such 
as in Africa, calls for the development of rapid diagnostic 
tools, especially ones that discriminate between active 
TB and LTBI. The use of commercial serological tests 
for diagnosing active TB has been strongly criticised, 
as a result of the poor accuracy of commercial tests in 
TB endemic settings [3], which is largely due to a high 
prevalence of LTBI [4–6]. However, further research in 
the field of antibody-based tests has been encouraged, as 
serological tests lend itself to the development of POC 
tests. Furthermore, it needs to be ascertained to what degree 
the lack of serological test specificity is due to a subgroup 
of LTBI with high risk for progression to active TB [4].
The standard strategy for TB treatment, directly 
observed treatment short course (DOTS) consists of a 
two month period of four drugs followed by another 
Table 1: Demographic characteristics of study participants
All TB LTBI QFT-negative ORD
Participants no. 63 21 21 21
Age, yr 34.1±11.3 41.0±10.5 26.0±3.6 35.2±12.2
M/F no. (%) 30(48)/33(52) 8(38)/13(62) 13(62)/8(38) 9(43)/12(57)
HIV status pos/neg 1/62 0/20 0/20 1/20
QFT-IT positive 42 21 21 Nil
Values are mean (±SD) unless indicated otherwise.
Figure 1: Plasma concentrations of serodiagnostic markers in TB and ORD. Concentrations of plasma serodiagnostic 
markers were measured in 21 TB patients, and 42 ORD cases. The ORD group comprised 21 LTBI individuals and 21 QFT-negative ORD. 
Representative plots are shown for diagnostic markers showing significant differences between groups and the vertical bars denote the 
mean and 95% confidence intervals. Corrections were applied within analyses of markers using Fischer Least Significant Differences post 
hoc test or Games- Howell post hoc test depending on homogeneity of variance. All the reported significant p-values were adjusted.
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four months of two anti-TB drugs [7]. The necessity of a 
treatment period of six month regimen is largely due to 
persistent bacilli that are not rapidly killed [8] and these 
persister organisms can be the cause of treatment failure and 
relapse [9]. The identification of better surrogate markers of 
treatment response than sputum culture would be a major 
boost towards enhancing treatment monitoring [10] and the 
potential role of serologic tests needs to be evaluated [11].
The main purpose of the present study was to 
evaluate the potential of IgG, IgA and IgM serodiagnostic 
markers for the diagnosis of active TB disease among 
people presenting with presumed TB at primary health 
care clinics and to explore their potential as treatment 
response markers.
RESULTS
Clinical and demographic characteristics of 
study participants
A total of 63 participants were included in the study. 
Out of these 63 individuals, 33 (52%) were females. The 
mean age of all study participants was 34.1±11.3 years and 
only one of the study participants was HIV positive. Using 
a pre-established diagnostic algorithm [12], 21 patients 
were classified as having TB disease. Of the 42 patients 
with other respiratory diseases (ORD), 21 were QFT-
negative (M. tuberculosis uninfected) while 21 individuals 
were latently infected (LTBI), as defined by a positive 
QFT-test using the manufacturer’s recommended cut-off 
value (≥0.35 IU/ml). Table 1 shows the demographic and 
baseline characteristics of the study participants.
Evaluation of antibodies for the diagnosis of 
active TB disease
The preparation of the recombinant proteins of 
M. tuberculosis antigens and the pre-coated IgG, IgA 
and IgM ELISA test kits by LIONEX Diagnostics and 
Therapeutics, Braunschweig, Germany has been described 
in detail in the respective methods section. In South 
Africa, we then measured and analyzed the titres of IgG, 
IgA and/or IgM antibodies against lipoarabinomannan 
(LAM) and 7 mycobacterial protein antigens (ESAT-6, 
Tpx, PstS1, AlaDH, MPT64, 16kDa and 19kDa) and 2 
antigen combinations (TUB, TB-LTBI) in plasma samples 
obtained from all 63 study participants (Table 1). When 
the antibody titres in the TB patients were compared to 
Table 2: Sensitivities and specificities of single serodiagnostic markers in differentiating active TB (n=21) from LTBI 
(n=21) and ORD (n=42)
Antigen Ig class
AUC TB vs ORD AUC TB vs LTBI
(95% CI) Sensitivity/specificity (%) (95% CI) Sensitivity/specificity (%)
AlaDH A 0.73(0.59-0.86) 0.76/0.69 0.73(0.57-0.89) 0.76/0.71
AlaDH G 0.63(0.49-0.76) 0.62/0.64 0.65(0.47-0.83) 0.76/0.57
ESAT-6 A 0.73(0.60-0.86) 0.67/0.79 0.75(0.61-0.89) 0.67/0.81
ESAT-6 G 0.46(0.27-0.65) 0.52/0.60 0.45(0.25-0.64) 0.52/0.52
LAM A 0.64(0.49-0.79) 0.52-0.76 0.59(0.41-0.76) 0.52/0.76
LAM G 0.91(0.83-0.98) 0.86/0.90 0.95(0.89-1.00) 0.86/0.95
MPT64 A 0.96(0.92-1.00) 0.95/0.90 0.97(0.91-1.00) 0.95/0.90
MPT64 G 0.69(0.56-0.82) 0.76/0.60 0.71(0.54-0.88) 0.76/0.67
PstS1 G 0.43(0.28-0.58) 0.52/0.52 0.51(0.32-0.70) 0.62/0.62
TB-LTBI A 0.76(0.63-0.88) 0.67/0.76 0.76(0.61-0.91) 0.67/0.86
TB-LTBI G 0.90(0.83-0.98) 0.90/0.79 0.89(0.78-0.99) 0.90/0.71
Tpx G 0.54(0.39-0.68) 0.55/0.57 0.52(0.34-0.70) 0.57/0.52
TUB A 0.74(0.62-0.87) 0.81/0.60 0.79(0.65-0.92) 0.81/0.62
16kDa A 0.93(0.87-0.99) 0.90/0.90 0.99(0.98-1.00) 0.95/0.95
16kDa G 0.77(0.66-0.89) 0.81/0.67 0.78(0.63-0.93) 0.95/0.62
16kDa M 0.84(0.74-0.94) 0.71/0.86 0.80(0.67-0.94) 0.71/0.81
19kDa A 0.60(0.49-0.72) 0.33/0.88 0.61(0.49-0.73) 0.33/0.90
19kDa G 0.76(0.63-0.88) 0.86/0.67 0.74(0.58-0.90) 0.86/0.67
Receiver operator curve (ROC) analysis was used in determining the accuracy (sensitivity/specificity) of each 
serodiagnostic marker. ORD individuals comprised 21 LTBI and 21 QFT-ve ORD. Abbreviations: Ig = Immunoglobin; vs = 
versus; AUC = Area under the curve; CI = Confidence Interval.
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the titres obtained in all individuals with other respiratory 
diseases ORD (regardless of QFT results), IgA antibodies 
against 16 kDa, AlaDH, ESAT-6, MPT64, IgG antibodies 
against 16 kDa, 19 kDa, LAM, TB-LTBI and IgM 
antibodies against 16 kDa antigen were significantly 
higher in TB patients compared to non-cases (Figure 
1). ROC curve analysis indicated that, anti-LAM IgG, 
anti-TB-LTBI IgG, anti-MPT64 IgA, and anti-16 kDa 
IgA antibodies were the leading single serodiagnostic 
markers (Table 2). Anti-MPT64 and 16 kDa antigen IgA 
ascertained TB disease with areas under the ROC curves 
(AUC) of 0.96 (95% CI, 0.92-1.00) and 0.93 (95% CI, 
0.87-0.99), respectively. The corresponding sensitivities 
and specificities were 95% / 90% and 90% / 90%, 
respectively (Table 2 and Figure 2).
Evaluation of antibodies in discriminating 
between active TB disease and LTBI
We performed a subgroup analysis and compared 
the antibody titres of the TB patients to those with other 
respiratory diseases who were QFT-positive. The IgA, 
IgG and IgM levels against 16 kDa, 19 kDa, AlaDH, 
ESAT-6, LAM, MPT64 and TB-LTBI protein antigens 
were significantly higher (p <0.01 in all cases) (Figure 
3). When the discriminative abilities of the different 
antibodies were evaluated by ROC curve analysis, the 
four antibodies anti-LAM IgG, anti-TB-LTBI IgG, 
anti-MPT64 IgA, and anti-16 kDa IgA were the most 
accurate. The AUC for anti-16 kDa IgA was 0.99 (95% 
CI, 0.98-1.00), and that for anti- MPT64 IgA was 
Figure 2: Receiver operator characteristics (ROC) curves of top single serodiagnostic markers for discriminating 21 
active tuberculosis patients from 42 other respiratory disease cases.
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0.97 (95% CI, 0.91-1.00) (Figure 4). Both antibodies 
differentiated between active TB and LTBI with a 
sensitivity of 95% and specificity ≥90%, respectively 
(Table 2).
Utility of multi-marker combinations to diagnose 
active TB
We evaluated the diagnostic abilities of 
combinations between the different antibodies 
in differentiating active TB from non-TB, or, 
alternatively from LTBI, using general discriminant 
analysis (GDA) models. For differentiating TB disease 
from other respiratory diseases, the most optimal 
biosignature was a three-marker serodiagnostic 
model comprising anti-TB-LTBI IgG, anti-Tpx IgG 
and anti-MPT64 IgA. This model correctly classified 
95.2% (20 from 21) of the TB patients and 97.6% 
(40 from 41) of the ORD cases in the resubstitution 
classification matrix, with an overall accuracy of 
96.8%, with the same level of accuracy after leave-
one-out cross validation (Table 3). For discriminating 
between active TB and LTBI, the before-mentioned 3 
markers plus anti-LAM IgA (a four-marker signature), 
classified both groups (TB disease or LTBI) with an 
accuracy of 100% in the resubstitution classification 
matrix, and an accuracy of 95.2% after leave-one-out 
cross validation (Table 3).
Figure 3: Plasma concentrations of serodiagnostic markers in individuals with tuberculosis, latently infected 
tuberculosis and QFT-negative other respiratory diseases. Concentrations of plasma serodiagnostic markers were measured in 
21 tuberculosis patients, 21 latently infected tuberculosis individuals and 21 QFT-negative other respiratory diseases. Representative plots 
are shown for diagnostic markers showing significant differences between groups and the vertical bars denote 95% confidence intervals. 
Significant difference between different groups p<0.05 is shown with the different alphabetical letters. The same alphabetical letters are 
used when there is no significant difference p>0.05 between the different groups. Corrections were applied within analyses of markers using 
Fischer Least Significant Differences post hoc testing or Games Howell post hoc depending on homogeneity of variance. All the reported 
significant p-values were adjusted.
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Differential antibody responses in TB patients 
undergoing anti-TB treatment
Next, we investigated whether antibodies reflect 
the response to TB treatment. This analysis was only 
done in the 19 out of the 21 active TB patients for whom 
samples were available at the end of anti-TB treatment 
because 2 of the patients with TB disease were lost to 
follow up. We found significant low pre-treatment IgG 
responses to LAM and the TB-LTBI antigen combination 
compared to M6 TB treatment. However, we observed 
decreased significant levels of anti-16 kDa IgA and anti-
16 kDa IgM after successful anti-TB treatment at M6 
(Figure 5).
DISCUSSION
The WHO does not support currently available 
commercial serologic tests for TB diagnosis but rather 
encourages further research to develop new tests with 
improved performance [3]. Performance targets for point-
of-care tests in adults with smear-positive pulmonary 
TB include a sensitivity and specificity of 95%, while 
sensitivity in smear-negative cases should attain 60-80% 
and specificity of 95%. In extrapulmonary TB, a sensitivity 
of 80% and specificity of 90% have been proposed [16]. 
The results of this current study suggest that IgA and 
IgG responses against highly purified known and also 
relatively novel mycobacterial antigens, are promising 
Figure 4: Receiving operating characteristics (ROC) curves of top single serodiagnostic markers for discriminating 21 
active tuberculosis patients from 21 latently infected individuals.
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due to the accuracies of individual and combination of 
marker above 95%. However, this is a small pilot study 
that requires further validation.
We have previously tested similar antibodies 
(anti-LAM IgG, anti-Tpx IgA). Results from the study 
showed that anti-LAM IgG was the best single marker 
discriminating TB from non-TB subjects and was also 
included in a five-marker combination with an improved 
performance. However, at that time, most of the controls 
were household contacts of active TB cases [6].
Previous studies have also found increased anti-
TB antigen antibody levels in LTBI participants [4, 5]. 
In contrast, in this study, we found that the inclusion of 
the LTBI group did not affect test performance. Future 
research should investigate, whether recent household 
contacts of active TB cases affects serology compared 
to non-household contacts with LTBI. It is unknown 
whether increased anti-TB antigen antibody levels 
characterize a subgroup of LTBI individuals with high 
risk for progression to active TB, whose identification via 
antibodies would urgently be desirable [4, 17–19].
Much emphasis has been placed on the evaluation 
of IgG in most serological studies [5, 20, 21] with less 
attention directed towards IgA or IgM [22, 23]. IgA is 
produced particularly at mucosal sites. Like IgG, both 
mucosal and systemic IgA have protective effects and 
can trigger pro-inflammatory response [24, 25]. And 
IgM is associated with acute infection. For these reasons, 
the evaluation of IgA and IgM antibodies, besides IgG, 
makes sense. In the present study, IgA were in part more 
accurate than their IgG counterparts. In a previous study 
by Legesse et al., [26] IgA responses to protein antigens 
(ESAT-6/CFP-10 and Rv2031) were also found to be more 
accurate for diagnosis of active TB than IgG responses in 
TB endemic settings.
The immunodiagnostic potential of several antigens 
has been reported [6, 27–29]. Out of all the antigens 
tested, LAM, the two proteins 16kDa and MPT64, and the 
antigen combination TB-LTBI best discriminated active 
TB from the other two groups with high sensitivity and 
specificity. The 16 kDa polypeptide is a member of the 
low molecular weight α-crystallin heat shock proteins. It 
is a dominant protein produced under oxygen starvation or 
passive growth phase and also important for the replication 
of bacteria in macrophages [30, 31]. In the present study, 
16 kDa elicited IgA, IgG and IgM responses in the plasma 
of the TB patients. Similarly, measuring 16 kDa antigen 
against all three isotypes, Raja and colleagues [32] found 
a combined specificity of 93% for serological detection 
in sputum and culture confirmed pulmonary TB patients. 
LAM is a component of the M. tuberculosis cell wall 
[33] and it is a well researched M. tuberculosis antigen 
for TB diagnosis in serological studies [6, 34, 35]. LAM 
elicited pronounced IgG responses in TB patients in this 





Resubstitution classification matrix Leave-one-out cross-validation
%TB % ORD % Accuracy % TB % ORD
Anti-TB-LTBI IgG 95.23 (20/1) 97.61 (1/41) 96.8 95.23 (20/1) 97.61 (1/41)
Anti-Tpx IgG
Anti-MPT64 IgA PPV: 0.95 (95% CI; 0.74-0.99)




Resubstitution classification matrix Leave-one-out cross-validation
%TB % LTBI % Accuracy % TB % LTBI
Anti-LAM IgA 100.0 (21/0) 100.0 (0/21) 100.0 95.23 (20/1) 95.23 (0/21)
Anti-TB-LTBI IgG
Anti-Tpx IgG
Anti-MPT64 IgA PPV: 0.95 (95% CI; 0.74-0.99)
NPV: 0.95 (95% CI; 0.75-0.99)
The predictive abilities of the optimal combination of serodiagnostic markers to differentiate between active TB (n=21), 
definite LTBI (n=21) (IGRA+) or ORD individuals (IGRA+ and IGRA- combined) (n=41) was investigated using best 
subsets general discriminant analysis and a leave-one-out cross-validation table was constructed using the variables that 
were included in the optimal classification model. PPV=Positive predictive value, NPV=Negative predictive value.
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study and this shows its potential in TB serodiagnostic 
even in endemic settings. Similarly, the serodiagnosis of 
active TB patients through LAM achieved a high degree 
of specificity [34]. In contrast to our previous study, IgG 
responses were only elicited by LAM in LTBI subjects 
compared to healthy controls. Antibodies against MPT64 
a highly specific protein that is secreted by M. tb, M. 
bovis and M. africanum [36–38] could be specific in the 
detection of TB especially as its expression is less in BCG 
vaccines [39]. An IgA response to MPT64 discriminated 
TB from QFT negative non-cases and LTBI with 
sensitivity of 95%. An MPT64 antibody aptamer, showed 
serological potential in the diagnosis of pulmonary TB in 
sputum smear positive as well as sputum smear negative 
patients [40].
The combination of IgA and IgG responses may help 
to increase accuracy of serodiagnostic tests for active TB 
disease in TB endemic settings, as previously suggested 
[6]. Accuracies of combinations of antibodies revealed 
that the combined IgG responses to Tpx and TB-LTBI 
and IgA response to MPT64 best discriminated active TB 
from ORD with a positive predictive value of 0.95 (95% 
CI; 0.74-0.99) and negative predictive value of 0.97 (95% 
CI; 0.85-0.99). The same antibody combinations with the 
inclusion of anti-LAM IgA were found to give the best 
discrimination between active TB and LTBI with positive 
and negative predictive values of 0.95(95% CI; 0.74-0.99) 
and 0.95(95% CI; 0.75-0.99) respectively. The multivariate 
analysis in our previous study with mainly TB household 
contacts [6] also revealed that both Tpx and LAM antigens 
Figure 5: Plasma concentrations of serodiagnostic markers of tuberculosis patients during anti-TB treatment. 
Concentrations of plasma serodiagnostic markers were measured in 21 TB patients at baseline (BSL) and in 19 TB patients who were 
followed up at end of month 6 anti-TB treatment. Representative plots are shown for diagnostic markers showing significant differences 
between the two time points and the vertical bars denote 95% confidence intervals. Corrections were applied within analyses of markers 
using Fischer Least Significant Differences post hoc testing or Games Howell post hoc depending on homogeneity of variance. All the 
reported significant p-values were adjusted.
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featured prominently in discriminating TB from non-TB 
with an accuracy of 86.2%. Also the serologic responses 
to these two consistent antigens should be further 
investigated in a well-designed cohort study. It has been 
suggested that using multi-antigen cocktails will increase 
the sensitivity of TB serodiagnosis above that of single 
antigens [41, 42]. This might be due to the differential 
expression of certain antigens during the stages of TB 
development [43, 44]. Of note, we mathematically found 
that also markers like anti-Tpx IgG and/or anti-LAM IgA, 
which performed less well in Univariate analysis (Table 
2), were valuable contributors in the Multivariate analysis 
(Table 3), as they complemented very well other well 
performing biomarkers, such as anti-PT-64 IgA and TB-
LTBI IgG (Table 3). In a way, anti-Tpx IgG and/or anti-
LAM IgA are able to detect other active TB cases than 
e.g. anti-MPT-64 IgA, a biomarker, which already had an 
accuracy >90% on its own. Additionally, as pointed out, 
an important point may be the combination of separately 
measured specific IgG and IgA antibodies.
We found a significant decrease in the levels of 
anti-16 kDa IgM and anti-16 kDa IgA after a successful 
completion of anti-TB treatment. Imaz and Zerbini [45] 
also reported decreased levels of antibodies, however, 
only three years after the start of anti-TB chemotherapy. 
A study on humoral response of TB patients undergoing 
anti-TB treatment indicated that antibody levels 
against other antigens had no association with anti-TB 
chemotherapy [46].
CONCLUSION
In summary, this study has shown that IgG and IgA 
antibody responses against single and multiple-antigen 
cocktails as well as multi-marker serologic models 
differentiated active cases from non-cases amongst people 
presenting with presumed TB regardless of LTBI status. 
Furthermore, our results suggest that the antibodies against 
the specific M. tuberculosis antigens tested in this study 
may be more useful for TB diagnosis than for monitoring 
treatment response. This result may encourage additional 
future efforts to investigate serologic responses in TB 
diagnostics research as such tests would be amenable to 
the development of rapid lateral flow-based test formats 
with application in field settings in a laboratory-free 
manner. However, future large scale prospective studies 
to include immunocompromised HIV co-infected patients 
are needed to further evaluate the validity of these results.
MATERIALS AND METHODS
Study population
Participants included in the present study were 
individuals presenting with signs and symptoms requiring 
investigation for TB, and were recruited as part of the 
recently concluded EDCTP-funded African European 
Tuberculosis Consortium (AE-TBC) study [12]. All 
study participants were recruited from a peripheral level 
health care centre, Fisantekraal, situated in the outskirts 
of Cape Town, South Africa. All participants presented 
with persistent cough lasting for more than 2 weeks and 
one of the following: fever, recent loss of weight, night 
sweats, haemolysis, chest pain or loss of appetite. The 
eligibility criteria for the study included age of between 
18 and 65 years, and willingness to give written informed 
consent including for HIV testing. The exclusion criteria 
included severe anaemia (HB<10g/l), current anti-TB 
treatment, anti-TB treatment in the last 90 days, or taking 
quinolone or aminoglycoside antibiotics in the past 60 
days, and not being resident in the study area for more 
than 3 months at presentation. Sputum samples were 
collected from all study participants and cultured using 
the MGIT method (BD Biosciences). Confirmation of the 
isolation of organisms of the M. tuberculosis complex in 
all positive cultures was carried by the Capilia TB test 
(TAUNS, Numazu, Japan). Additionally, 3 ml of blood 
were collected from the participants for the performance 
Table 4: Recombinant antigens of M. tuberculosis used in this study
Antigens of M. tuberculosis Rv no. Mol.mass (kDa) Reference(s) Ig class
19 kDa glycolipoprotein, LpqH Rv3763 16 [4] IgA, IgG
AlaDH Rv2780 38.7 [14] IgA, IgG
ESAT-6 Rv3875 9.9 [11] IgA, IgG
HSP16.3, HSPX, 14 kDa, 16 kDa, 
ACR Rv2031c 16.3 [6] IgA, IgG, IgM
LAM – – IgA, IgG
MPT64 Rv1980c 24.8 [47] IgA, IgG
PstS1, 38 kDa Rv0934 38.2 [15] IgG
Tpx, CFP20 Rv1932 16.9 [11] IgA, IgG
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of Quantiferon-in Tube (QFT-IT) assay (Qiagen), 
which was carried out according to the manufacturer’s 
instruction as previously described [13]. For the current 
study, we included 21 patients with culture positive TB 
and 42 with other lung diseases of which 21 had LTBI 
as defined by a positive QFT test and of which 21 were 
QFT-negative. These participants were randomly selected 
from Stellenbosch set of samples from the main study and 
according to availability of baseline and month 6 samples. 
All active TB patients received standard TB treatment 
according to South African National Tuberculosis 
Program and samples were collected from 19 of the TB 
participants at the end of TB treatment at month 6. This 
means, that out of the original 21 TB patients, samples 
were only collected from 19 of the participants at the end 
of month 6 TB treatment as two participants were lost 
due to follow up. None of the non-TB patients (LTBI 
and the QFT-negative) received anti-TB treatment. 
Ethical approval for the study was obtained from the 
Health Research Ethics Committee of the University of 
Stellenbosch (reference number N10/08/274) and written 
informed consent was obtained from each participant 
before the study.
Sample collection and preparation
At enrolment, 10ml of whole blood were collected 
from all study participants directly into heparinized BD 
vacutainer tubes (BD Biosciences), and transported at 
ambient conditions within two hours of collection to the 
laboratory. The tubes were then centrifuged at 1200xg 
for 10 minutes, and plasma harvested and stored at -80°C 
until further use. Sample collection was repeated for 19 
TB patients at months 6 following anti-TB treatment.
Antigen preparation
Seven cloned and purified recombinant proteins of 
M. tuberculosis (Table 4) were used in the present study. 
For MPT64 expression, recombinant M. smegmatis mc2 
155 cells containing the MPT64 expression plasmid (with 
C-terminal histidine tag) were grown in animal source-
free medium at 37°C overnight. The recombinant MPT64 
was secreted into the culture medium by constitutive 
expression. The medium was harvested by centrifugation 
followed by buffer exchange on a Sephadex G25 column 
(GE Healthcare) into 10 mM NH4HCO3 buffer. The protein 
containing solution was applied onto Ni-NTA Superflow 
resin (Qiagen). MPT64 was eluted in a linear imidazole 
gradient. Highly pure MPT64-containing fractions 
were pooled and underwent a final buffer exchange on 
a Sephadex G25 column (GE Healthcare) into 10 mM 
NH4HCO3, pH 8,0. Aliquots of the protein solution were 
freeze-dried and stored below -20 °C. The production 
of the remaining protein antigens has been described 
previously: 19 kDa [4], AlaDH [14], ESAT-6 [11], 16 
kDa [6], PstS1 [15], and Tpx [11]. We also evaluated two 
multiple antigen cocktails in this study. The first multiple 
antigen cocktail TUB contains PstS1, 16kDa and APA 
while the second TB-LTBI is composed of Tpx and L16. 
All recombinant proteins of M. tuberculosis antigens 
were prepared by LIONEX Diagnostics and Therapeutics, 
Braunschweig, Germany. A sample of highly purified 
M. tuberculosis LAM was kindly provided by Dr. Arend 
Kolk, Amsterdam.
Enzyme-linked immunosorbent assay
All pre-coated IgG, IgA and IgM ELISA test kits 
and reagents against M. tuberculosis antigens were 
provided by LIONEX Diagnostics and Therapeutics, 
Braunschweig, Germany. The actual ELISA measurements 
of the human plasma samples were performed in South 
Africa, including the evaluation of the results. In brief, 
human plasma was diluted 1:200 in PBS pH 7.5/0.05% 
BSA buffer. One hundred μl of the diluted plasma and 
ready-to-use standards were pipetted into the antigen-
coated wells of the microtiter plate in duplicates. After 60 
minutes incubation while shaking (45 minutes incubation 
for Immunoglobulin (Ig) M) at 37°C, the well contents 
were emptied and plates washed three times with 300 
μl/well PBS-T (0.15 M PBS, pH 7.5/0.05% Tween-20). 
100 μl/well of ready to use anti-human-IgG-conjugate 
(diluted 1:40 000), anti-human-IgA (1:12 000) or anti-
human-IgM (1:12 000) antibodies were added to the wells 
and the plates incubated for 30 minutes at 37°C while 
shaking. After a second washing step, the enzyme activity 
was assayed by rapidly adding 100 μl/well of substrate 
tetramethylbenzidine (TMB) with a further incubation for 
20 minutes at 37°C in the dark. The colour development 
was ended by the rapid addition of 100 μl/well 0.2 M 
H2SO4 stop solution. The absorbance was measured at 
450 nm (OD450) with a 620 nm (OD620) reference filter 
using an automatic microplate reader (iMark™ Microplate 
absorbance reader, BIO RAD, USA). The mean OD of the 
blank wells was subtracted from the sample values.
Statistical analysis
For the evaluation of the diagnostic potential 
of serodiagnostic markers, statistical differences in 
the concentrations of markers between active TB 
and individuals with other respiratory diseases were 
analysed by analysis of variance (ANOVA) with Fisher 
Least Significant Difference (LSD) post hoc test or 
Mann-Whitney U test depending on the normality of 
the distribution. In cases where Levene’s test rejected 
the assumption of homogeneity of variance, weighted 
means were reported and the Games-Howell post-
hoc test conducted. Receiver operating characteristics 
(ROC) curve analysis was used in evaluating the 
accuracy of the different markers. To investigate the 
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predictive abilities for the optimal combination of 
serodiagnostic markers for differentiating TB disease 
and individuals with ORD, general discriminant analysis 
(GDA) was performed. The best subsets method was 
employed in determining optimal subsets of variables 
that gave the best prediction. Using the best variables 
that were included in the optimal classification model, 
a leave-one-out cross validation table was constructed. 
For the investigation of markers that could be useful 
in monitoring of the response to TB treatment, the 
change in the concentrations of markers during TB 
treatment was analyzed using mixed model repeated 
measures analysis of variance (ANOVA) with Fisher 
Least Significant Difference (LSD) post hoc test. A 
level of 5% significance was used as a guideline for the 
determination of significance associations. All statistical 
analysis except ROC analysis was performed using 
Statistica software (Statsoft, Ohio, USA). ROC analysis 
was done using R program language.
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